AMAG Pharmaceuticals EPS Q / Q

¿Qué es el EPS Q / Q de AMAG Pharmaceuticals?

El EPS Q / Q de AMAG Pharmaceuticals, Inc. es -383.33%

¿Cuál es la definición de EPS Q / Q?



La tasa de crecimiento trimestral del EPS, trimestre a trimestre , es el aumento del EPS de la compañía en los últimos 4 trimestres en comparación con el comportamiento de los 4 trimestres anteriores.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Q / Q de compañías en Sector Health Care en NASDAQ en comparadas con AMAG Pharmaceuticals

¿Qué hace AMAG Pharmaceuticals?

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Empresas con eps q / q similar a AMAG Pharmaceuticals